Way oversold. It is always a risk to invest in dual outcome based stocks such as biotech or resources. Atleast PAR is not a one trick pony. They still have other irons in the fire. We just need one of them to do well as the target markets are huge and this company will rerate massively. While today's results are very disappointing, this is not the end for the company. I haven't sold any and will look to add more potentially in the coming weeks.
Ann: Hay Fever Trial Update, page-4
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.055(20.4%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 33.5¢ | 27.5¢ | $1.328M | 4.323M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 152597 | 4 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
